News Breaks |
|
|
| February 28, 2013 |
| 05:55 EDT |  | MDT, MDT, COV, COV, INTC, INTC, BSX, BSX, VRTX, VRTX, JNJ, JNJ | Opal to host a summit
4th Annual Medical Devices Summit is being held in Boston on February 28-March 1. |
|
|
News For MDT;COV;INTC;BSX;VRTX;JNJ From The Last 14 Days Check below for free stories on MDT;COV;INTC;BSX;VRTX;JNJ the last two weeks. |
|
|
| May 22, 2013 |
| 12:22 EDT |  | BSX | Boston Scientific says new data shows blood pressure reduction with Vessix
Boston Scientific reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained reduction in the blood pressure of patients treated with the Vessix Renal Denervation System. Data on the first 41 subjects enrolled in the REDUCE-HTN clinical program were presented at the annual EuroPCR Scientific Program in Paris. Interim data highlights include: All patients underwent successful bilateral renal denervation treatment; At the primary endpoint of six months, patients experienced a significant 27.6 mmHg reduction in systolic blood pressure; No device-related adverse events or procedural renal artery complications were reported; Long term efficacy was demonstrated, with a sustained 28.4 mmHg reduction in systolic blood pressure in the subset of patients for whom 12-month data are available; Demonstrated success in treating various anatomies, including accessory renal arteries; Demonstrated short renal denervation procedural time. |
|
| 10:44 EDT | | BSX | Boston Scientific says Lotus system met primary performance endpoint in trial
 Subscribe for More Information |
|
| 09:35 EDT | | BSX | Boston Scientific says trials show 'exceptional' safety, efficacy data on stents
Boston Scientific reported positive results from two trials evaluating new, innovative drug-eluting stent technologies, which are emerging treatment options for coronary heart disease. Data from the first human use NG PROMUS Clinical Trial evaluating the safety and effectiveness of the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, and two-year follow-up data from the EVOLVE Trial comparing the safety and effectiveness of the SYNERGY Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent System to the PROMUS Element Stent System were presented at the annual EuroPCR Scientific Program in Paris. The primary investigator for one trial said, "The Promus PREMIER Stent demonstrated excellent safety and effectiveness with zero percent target lesion revascularization and stent thrombosis. In addition, the rate of technical success, the primary endpoint of the trial, was very high at 99.2%." |
|
| 09:10 EDT | | INTC | Intel management to meet with Deutsche Bank
Subscribe for More Information |
|
| 07:48 EDT | | MDT | FDA Orthopaedic and Rehabilitation Devices Panel to hold a meeting
Subscribe for More Information |
|
| 07:24 EDT | | INTC | NetEvents International to host a summit
Subscribe for More Information |
|
| 07:21 EDT | | INTC | MIT Sloan Alumni Club of Boston to hold a symposium
Subscribe for More Information |
|
| 07:00 EDT | | COV | Covidien announces positive results from clinical trial on endoscopic therapy
Subscribe for More Information |
|
| May 21, 2013 |
| 13:08 EDT |  | INTC | Intel CEO creates 'new devices' group, Reuters reports
Subscribe for More Information |
|
| 13:02 EDT | | MDT | Medtronic announces CE Mark for CapSureFix Novus
Medtronic announced CE Mark and launch of its CapSureFix Novus 5076 Lead, which is now approved in the EU for use in an MRI environment when paired with a Medtronic MR-Conditional pacemaker. The lead has not been approved for that use in the U.S. |
| |
| 11:49 EDT | | BSX | Boston Scientific data show Bronchial Thermoplasty benefits for up to five years
Subscribe for More Information |
|
| 11:38 EDT |  | MDT | High option volume stocks: KOS MWE HGG SOL MDT
|
|
| 09:25 EDT | | MDT | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 07:24 EDT | | JNJ | Global Health Care to host a conference
Subscribe for More Information |
|
| 07:19 EDT |  | MDT | Medtronic sees FY14 EPS $3.80-$3.85, consensus $3.84
Sees FY14 revenue growth up 3%-4% on a constant currency basis. |
|
| 07:17 EDT | | MDT | Medtronic reports Q4 EPS $1.10, consensus $1.03
Subscribe for More Information |
|
| 05:54 EDT | | MDT | Medtronic announces primary results from Global Symplicity Registry
Subscribe for More Information |
|
| 05:51 EDT | | MDT | Medtronic CoreValue ADVANCE study shows low mortality rates
Subscribe for More Information |
|
| 05:48 EDT | | BSX | OrbusNeich seizes Boston Scientific stents as part of patent infringement case
Subscribe for More Information |
|
| May 20, 2013 |
| 15:22 EDT | | MDT | Notable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Home Depot (HD), consensus 77c; Medtronic (MDT), consensus $1.03; The TJX Companies (TJX), consensus 62c; AutoZone (AZO), consensus $7.23; Best Buy (BBY), consensus 25c; Dick's Sporting Goods (DKS), consensus 48c; Tidewater (TDW), consensus 61c; Saks (SKS), consensus 19c; Rexnord (RXN), consensus 31c; Monro Muffler Brake (MNRO), consensus 25c. |
| |
|
|
|
|
